Navigation Links
Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
Date:8/5/2008

- Phase IIb study examines efficacy and safety of once-daily TMC278 in

treatment-naive adults with HIV-1 -

MEXICO CITY, Aug. 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of HIV combination therapy in treatment-naive adults. These findings were presented today at the International AIDS Conference (AIDS 2008) in Mexico City.

Seventy-six percent of patients receiving the 25 mg dose of TMC278, which is being studied in phase III trials, achieved an undetectable viral load (<50 HIV-1 RNA copies/mL) at week 96 compared with 71 percent of patients receiving efavirenz (EFV). Of patients receiving the 75 mg and 150 mg doses of TMC278, 72 percent and 71 percent achieved an undetectable viral load, respectively.

"NNRTIs have been an integral part of combination antiretroviral therapy for over a decade," said clinical trial investigator Peter Shalit, M.D. Swedish Medical Center, Seattle, WA. "The phase IIb data show potential for TMC278 as a once-daily treatment option for patients who have not previously taken anti-HIV medications."

TMC278 is an investigational product, and the safety and efficacy of it, in combination with other antiretroviral agents, has not been established. Two major phase III trials for TMC278 are being conducted in Africa, Asia, Europe, North America and South America, and are currently recruiting treatment-naive adult patients.

Study Design

The phase IIb dose-finding study (TMC278-C204) evaluated the efficacy, tolerability and safety of once-daily TMC278 at three blinded doses (25 mg, 75 mg, and 150 mg) and included an open label EFV 600 mg arm. A total of 368 patients were randomised to receive one of the three doses of TMC278 or EFV, and all patients received a background regimen of two nucleoside reverse transcriptase inhibitors (NRTIs), zidovudine + lamivudine (AZT/3TC) or tenofovir + emtricitabine (TDF/FTC).

Safety Results

Of patients in the TMC278 combined group compared with EFV, 9 percent vs. 21 percent experienced rash, 31 percent vs. 48 percent experienced nervous system adverse events and 16 percent vs. 21 percent experienced psychiatric events.

Overall, patients in the TMC278 combined group (all doses) vs. the EFV group experienced similar incidences and types of serious adverse events (SAEs) (12 percent vs. 15 percent), grade 3 or 4 adverse events (AEs), (27 percent vs. 21 percent) and grade 3 or 4 laboratory abnormalities (26 percent vs. 24 percent).

TMC278 is the third anti-HIV compound to be developed by Tibotec Pharmaceuticals, which is also developing investigational compounds for the treatment of hepatitis C and tuberculosis.

About Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Media Contacts:

Karen Manson - 32-479-89-47-99

Pam Van Houten - 908-295-7367

Investor Relations Contacts:

Lesley Fishman - 732-542-3922

Louise Mehrota - 732-524-6491


'/>"/>
SOURCE Tibotec Pharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
2. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
5. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
6. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
9. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
10. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
11. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017  Demonstrating its commitment to representing research- ... the Pharmaceutical Research and Manufacturers of America (PhRMA) ... will now have to meet new research and ... to join PhRMA. "By putting in ... a clear message that being a member of ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician in ... cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a ... first in Arkansas to introduce the most powerful SCS system and the only stretchable ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the ... narrowly passed the U.S. House on May 4, would result in 23 million Americans ... continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , ...
(Date:5/26/2017)... ... 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in ... post on insurance options. If a Bay Area patient has to search for a ... money. Visiting an in-network provider for a second opinion can ensure a patient receives ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the story ... “Cactus Jack: Against All Odds” is the creation of published author, Walter Hubbard, ... married to Jack Carlisle’s third child Jane. Walter. Walter and Jane have three ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., ... nVerge 2017 – a one-day technology conference in San Diego, CA. , At ... allows users to fully utilize and enhance their Sage ERP solutions by providing improved ...
Breaking Medicine News(10 mins):